Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186965 | 0.86 | HCAR3 (0.60) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL20515889 | 0.84 | KMT2A (0.49) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL19763766 | 0.84 | KMT2A (0.49) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL19763764 | 0.84 | KMT2A (0.49) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL28934823 | 0.83 | POLB (0.48) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL5599411 | 0.83 | KMT2A (0.48) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL25427901 | 0.82 | MAPK1 (0.59) | KMT2AL3MBTL1POLBCYP1A2HCAR3 | |
| SCHEMBL24428117 | 0.81 | KMT2A (0.46) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL19224665 | 0.79 | KMT2A (0.52) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL1665229 | 0.78 | DAO (0.58) | KMT2ANPSR1L3MBTL1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-116897152-A | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-115403524-A | Preparation method of 3-fluoro-pyrazole carboxylate and 3-fluoroalkyl-1-substituted pyrazole-4-carboxylic acid | 浙江省化工研究院有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | KMT2A 4450/4885NPSR1 782/4885L3MBTL1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.